查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1881612

神经系统生物标记免疫分析市场－全球产业规模、份额、趋势、机会和预测，按产品、疾病、应用、地区和竞争格局划分，2020-2030年预测

Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球神经生物标记免疫分析市场规模为6.5422亿美元，预计2030年将以11.65%的复合年增长率成长至12.6729亿美元。神经生物标记免疫分析包括基于蛋白质的检测方法，旨在检测和量化生物样本中指示神经系统疾病的特定分子相互作用。全球此类诊断市场的主要驱动力是神经退化性疾病盛行率的不断上升以及对早期精准诊断工具日益增长的需求。

市场概览
预测期 2026-2030
2024年市场规模 6.5422亿美元
2030年市场规模 12.6729亿美元
2025-2030年复合年增长率 11.65%
成长最快的细分市场 试剂
最大的市场 北美洲

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球神经生物标记免疫分析市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品分类（仪器、试剂、服务）
    • 依疾病分类（阿兹海默症、帕金森氏症、多发性硬化症、其他）
    • 依应用领域（体外诊断、研究）
    • 按地区
    • 按公司（2024 年）
  • 市场地图

第六章：北美神经生物标记免疫分析市场展望

  • 市场规模及预测
  • 市占率及预测
    • ¬因疾病
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲神经生物标记免疫分析市场展望

  • 市场规模及预测
  • 市占率及预测
    • ¬因疾病
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区神经生物标记免疫分析市场展望

  • 市场规模及预测
  • 市占率及预测
    • ¬因疾病
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲神经生物标记免疫分析市场展望

  • 市场规模及预测
  • 市占率及预测
    • ¬因疾病
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲神经生物标记免疫分析市场展望

  • 市场规模及预测
  • 市占率及预测
    • ¬因疾病
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最新进展

第十三章：全球神经生物标记免疫分析市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • QIAGEN NV
  • Abbott Laboratories Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • F. Hoffmann La-Roche Ltd.
  • Nimble Therapeutics Inc.
  • HD Biosciences Co., Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 20976

The Global Immunoassay for Neurological Biomarkers Market, valued at USD 654.22 Million in 2024, is projected to experience a CAGR of 11.65% to reach USD 1267.29 Million by 2030. Immunoassays for neurological biomarkers encompass protein-based tests designed to detect and quantify specific molecular interactions indicative of neurological disorders within biological samples. The global market for these diagnostics is primarily driven by the escalating prevalence of neurodegenerative conditions and the increasing demand for early and precise diagnostic tools.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 654.22 Million
Market Size 2030USD 1267.29 Million
CAGR 2025-203011.65%
Fastest Growing SegmentReagents
Largest MarketNorth America

Key Market Drivers

The increasing prevalence of neurological disorders globally constitutes a primary impetus for the immunoassay market for neurological biomarkers. The increasing longevity of the global population, coupled with environmental and lifestyle factors, contributes to a rising burden of neurodegenerative conditions. For instance, according to a study published in The Lancet in March 2024, the Global Burden of Disease, Injuries, and Risk Factors study 2021 revealed that 3.4 billion people, representing 43% of the world's population, were affected by neurological conditions in 2021. This widespread occurrence underscores an urgent clinical need for accurate and accessible diagnostic and monitoring tools, driving demand for advanced biomarker detection and effective therapeutic intervention development.

Key Market Challenges

The market for immunoassays in neurological biomarkers faces significant impedance due to stringent regulatory hurdles and the inherent complexity of standardizing biomarker panels. These obstacles directly constrain the introduction of novel assays and complicate their widespread clinical adoption. For instance, according to MedTech Europe's 2024 survey results, which includes data up to October 2023, certification and maintenance costs for in vitro diagnostic (IVD) devices under the new European IVD Regulation (IVDR) have escalated by 10% or more compared to previous directives, diverting substantial personnel and financial resources away from innovation and market expansion. This increase in regulatory burden and cost creates unpredictable timelines for manufacturers, particularly impacting smaller and medium-sized enterprises.

Key Market Trends

The integration of Artificial Intelligence for enhanced biomarker detection and analysis significantly impacts the immunoassay market for neurological biomarkers. AI algorithms process complex multimodal data, including imaging and clinical records, identifying subtle biomarker patterns crucial for diagnosing neurological disorders. This capability enables precise disease stratification and personalized therapeutic approaches. According to AdvaMed, in 2022, at least 91 new algorithms gained FDA approval in the first ten months, impacting diagnostic markets. Illustrating this, the University of Liverpool announced in October 2025 the development of a low-cost, handheld AI-powered blood test for early Alzheimer's detection. This innovation highlights AI's role in advancing accurate diagnostic tools.

Key Market Players

  • QIAGEN NV
  • Abbott Laboratories Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • F. Hoffmann La-Roche Ltd.
  • Nimble Therapeutics Inc.
  • HD Biosciences Co., Ltd.

Report Scope:

In this report, the Global Immunoassay for Neurological Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoassay for Neurological Biomarkers Market, By Product:

  • Instruments
  • Reagents
  • Services

Immunoassay for Neurological Biomarkers Market, By Disease:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others

Immunoassay for Neurological Biomarkers Market, By Application:

  • In Vitro Diagnostics
  • Research

Immunoassay for Neurological Biomarkers Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Immunoassay for Neurological Biomarkers Market.

Available Customizations:

Global Immunoassay for Neurological Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunoassay for Neurological Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Reagents, Services)
    • 5.2.2. By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others)
    • 5.2.3. By Application (In Vitro Diagnostics, Research)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Immunoassay for Neurological Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Disease
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By Application

7. Europe Immunoassay for Neurological Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Disease
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By Application
    • 7.3.2. France Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By Application

8. Asia Pacific Immunoassay for Neurological Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Disease
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By Application
    • 8.3.2. India Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By Application

9. Middle East & Africa Immunoassay for Neurological Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Disease
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By Application

10. South America Immunoassay for Neurological Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Disease
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Immunoassay for Neurological Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN NV
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Merck & Co., Inc.
  • 15.4. Johnson & Johnson Services, Inc.
  • 15.5. Thermo Fisher Scientific, Inc.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Sysmex Corporation
  • 15.8. F. Hoffmann La-Roche Ltd.
  • 15.9. Nimble Therapeutics Inc.
  • 15.10. HD Biosciences Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer